Olfactive Biosolutions develops Pivit wellness formulations that utilize food-based molecules to activate ectopic receptors in the body. These proprietary products target metabolic functions like insulin secretion and fat oxidation to promote health benefits without synthetic hormones or pharmaceuticals. The company offers Pivit formulations for licensing to CPG and wellness sectors, alongside a direct-to-consumer weight loss product.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical drugs for weight loss and blood sugar regulation can have significant side effects and may not be accessible or affordable for everyone. These drugs often rely on synthetic compounds, whereas natural alternatives with fewer adverse effects are desirable.
Solution
Olfactive Biosolutions develops patented formulations of food molecules that activate ectopic receptors in the body, mimicking the physiological effects of pharmaceuticals for weight loss and blood sugar regulation. Their Protenx line offers a natural alternative to traditional drugs by using food-derived ingredients to stimulate the release of GLP-1 and GIP, which regulate glucose and lipid metabolism. By tuning these formulations to activate specific receptors like OR51E1 in the gut, Protenx aims to provide consistent GLP-1 production, mirroring the effects of weight loss drugs but with fewer side effects. These formulations can be added to everyday products like coffee, energy bars, and drinks.
Target Audience
The primary target audience includes consumers seeking natural alternatives to pharmaceutical drugs for weight loss and blood sugar regulation, as well as food and beverage, consumer packaged goods, ingredients, and health and wellness companies.
Features
- Patented formulations of food molecules designed to activate ectopic receptors.
- Mimics the effects of GLP-1 and GIP for weight loss and blood sugar regulation.
- Utilizes natural ingredients derived from fruits, vegetables, and herbs.
- Targets specific receptors like OR51E1 to stimulate natural GLP-1 production.
- Can be incorporated into various food and beverage products.
- Aims to provide similar benefits to pharmaceutical drugs with reduced side effects.
- Holds U.S. patents 12,115,134, 12,102,664, and 12,102,611 related to treating endocrine diseases and hypertension.